Moderna (NASDAQ:MRNA – Get Free Report) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Moderna to related businesses based on the strength of its risk, analyst recommendations, earnings, institutional ownership, valuation, profitability and dividends.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Moderna and its peers, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Moderna | 4 | 15 | 6 | 0 | 2.08 |
| Moderna Competitors | 9847 | 15133 | 45517 | 1589 | 2.54 |
Moderna currently has a consensus price target of $113.75, indicating a potential downside of 55.53%. As a group, “Biotechnology” companies have a potential upside of 102.75%. Given Moderna’s peers stronger consensus rating and higher probable upside, analysts plainly believe Moderna has less favorable growth aspects than its peers.
Volatility and Risk
Moderna has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500. Comparatively, Moderna’s peers have a beta of 1.14, suggesting that their average stock price is 14% more volatile than the S&P 500.
Profitability
This table compares Moderna and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Moderna | -141.43% | -28.30% | -19.39% |
| Moderna Competitors | -12,359.35% | -203.09% | -30.93% |
Insider & Institutional Ownership
75.3% of Moderna shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 10.8% of Moderna shares are held by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Moderna and its peers revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Moderna | $1.94 billion | -$2.82 billion | -36.03 |
| Moderna Competitors | $698.13 million | $10.43 million | -15.34 |
Moderna has higher revenue, but lower earnings than its peers. Moderna is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Summary
Moderna peers beat Moderna on 7 of the 13 factors compared.
Moderna Company Profile
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.
